anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Dysregulation of bile acids (BAs), as important signalling molecules in regulating lipid and glucose metabolism, contributes to the development of non-alcoholic fatty liver disease (NAFLD). However, static BA profiles during fasting may obscure certain pathogenetic aspects. In this study, we investigate the dynamic alterations of BAs in response to an oral glucose tolerance test (OGTT) among children with NAFLD.
METHODS: We recruited 230 subjects, including children with overweight/obesity, or complicated with NAFLD, and healthy controls. Serum BAs, 7-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19 (FGF19) were quantified during OGTT. Clinical markers related to liver function, lipid metabolism and glucose metabolism were assessed at baseline or during OGTT.
FINDINGS: Conjugated BAs increased while unconjugated ones decreased after glucose uptake. Most BAs were blunted in response to glucose in NAFLD (p > .05); only glycine and taurine-conjugated chenodeoxycholic acid (CDCA) and cholic acid (CA) were responsive (p < .05). Primary BAs were significantly increased while secondary BAs were decreased in NAFLD. C4 and FGF19 were significantly increased while their ratio FGF19/C4 ratio was decreased in NAFLD. The dynamic pattern of CDCA and taurine-conjugated hyocholic acid (THCA) species was closely correlated with glucose (correlation coefficient r = .175 and -.233, p < .05), insulin (r = .327 and -.236, p < .05) and c-peptide (r = .318 and -.238, p < .05). Among which, CDCA was positively associated with liver fat content in NAFLD (r = .438, p < .05). Additionally, glycochenodeoxycholic acid (GCDCA), CDCA and THCA were potential biomarkers to discriminate paediatric NAFLD from healthy controls and children with obesity.
INTERPRETATION: This study provides novel insights into the dynamics of BAs during OGTT in paediatric NAFLD. The observed variations in CDCA and HCA species were associated with liver dysfunction, dyslipidaemia and dysglycaemia, highlighting their potential roles as promising diagnostic and therapeutic targets in NAFLD.
FIELD: medicine, veterinary science and food industry. SUBSTANCE: present invention describes method of preparing ecological lignin sorbent by treating hydrolysis lignin with reagents, extracting the extract and drying. Lignin is subjected to grinding and two stage treatment: lignin is first treated with 40-96 % ethanol for at 20-50 C 50-80 minutes or with water at 120 C for 15-30 minutes, or with water at 80-100 C for 50-80 minutes, and at second stage lignin is subjected to boiling in water for 1 hour two times, and each time extract is removed. Ballast compounds are removed from hydrolysis lignin, and agent is obtained. Said agent has high sorption properties as sterilization resistant and has sterility that does not shift pH of aqueous media. This is essential for safe use when agent is contacted with blood, milk or other biological liquids to be successfully used in medicine and biotechnology. EFFECT: more efficient preparation method. 4 cl, 2 tbl
This arm will display a "Calories per Bottle" label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current "Clear on Calories" labels (as of 2018).
Compsns. comprising O3 dispersed in a carrier are new. Also claimed is a device for the treatment of humans, animals or articles with an O3-contg. medium, comprising an O2 source, an ozoniser, a diffuser for dispersing the O3 in a carrier, and a treatment reservoir for receiving the O3-contg. carrier. Also claimed is a device for producing an O3 contg. medium, comprising an O2 source, an ozoniser, a diffuser and opt. means for filling containers with the medium.
This group comprises 60 patients aged 12 to 17 diagnosed with an eating disorder. They must have shown poor response to treatment, defined as having one of the two conditions: 1) undergoing over a year of treatment, including partial and total hospitalization, without symptom stabilization (needing high-intensive treatment units i.e. not being able to follow individual treatment in external consultations); 2) having more than three admissions without symptom stabilization in less than one year. They will be recruited from child/adolescent ED units in Catalonia. Exclusions will be acute ED pathology requiring urgent pediatric attention or admission to an acute psychiatric ward.
Bipolar depression remains the great unmet need in the treatment of bipolar disorder. Only two treatments have been FDA-approved for the management of acute bipolar depression (the combination of olanzapine and fluoxetine and quetiapine). Early pilot data suggests the drug minocycline has potent antidepressant effects. Minocycline is approved by the Food and Drug Administration (FDA) (for acne and bacterial infections), is inexpensive and readily available in generic formulation, and is generally well-tolerated. This study will examine whether administering the drug minocycline to individuals with bipolar depression over 8 weeks will improve their depressive symptoms. This study will also offer an option to participate in proton magnetic resonance spectroscopy (1H-MRS) to measure N-Acetylaspartate (NAA) levels in the brain, which are thought to be decreased in bipolar disorder.
The present invention provides a liposomal composition, method of using a liposomal composition, and devices and modes of operation of the devices and of the compositions, and kits related thereto. The invention provides for the reverse transport of cholesterol from peripheral tissues to the liver in a warm blooded mammal while controlling plasma atherogenic lipoprotein concentrations, including LDL concentrations. The method and mode of operation of the devices includes the step of administering an effective amount of a multiplicity of acceptors comprised of phospholipids substantially free of sterol. The method optionally includes the step of periodically assaying atherogenic lipoprotein concentrations with an assay during the treatment period to assess atherogenic lipoprotein concentrations and obtain an atherogenic lipoprotein profile, and adjusting the administration in response to said profile. The large liposomes are dimensioned larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver so that the liposomes are too large to readily penetrate the fenestrations of one variant.  The therapeutically effective amounts are in the range of about 10 mg to about 1600 mg phospholipid per kg body weight per dose. A pharmaceutical composition and related kit for mobilizing peripheral cholesterol and sphingomyelin that enters the liver of a subject consisting essentially of liposomes of a size and shape larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver is also provided. The invention also provides for control of cholesterol related genes and other compounds.
All participants took part in the 6-week exercise program, as well as in the two evaluation sessions (pre- and post- exercise program). At the initial evaluation, subjects completed forms and questionnaires on sociodemographics, symptomatology, comorbidities, work restrictions, pain and functional limitations and fear-avoidance beliefs. A physiotherapist measured their lumbar and hip mobility, conducted diagnostic and pain provocation tests and assessed endurance of the trunk muscles. Following the initial evaluation, subjects took part in the 6-week multi-station full-body supervised exercise program (2 to 3 sessions per week). The Oswestry disability questionnaire (ODI) was completed at the initial and at the final evaluations. The change in ODI score following the program was considered the principal measure reflecting favorable or unfavorable outcome.

An improvement of 50% in the initial ODI score was considered the reference standard to determine a favorable outcome. Univariate associations with favorable outcome were tested using chi-square or paired t-tests. Variables that showed between-group (favorable/unfavorable) differences were entered into a logistic regression after determining the sampling adequacy. Finally, continuous variables were dichotomized and the sensitivity, specificity and positive and negative likelihood ratios were determined for the model and for each variable.
AIM: IL32 is a pleiotropic intracellular cytokine with an emergent role in tuberculosis. The different isoforms of IL32: α, β, γ and δ have varying pro and anti-inflammatory potentials. We studied the role of genetic variants of IL32 and its isoforms in susceptibility to tuberculosis using a case-household contact association study.
METHODOLOGY: Using a targeted sequencing approach, IL32 (+1kb) gene was sequenced in 64 pairs of culture positive TB cases and their culture negative household contacts. Subsequently the identified variants were validated in an independent cohort of cases and household contacts using TaqMan genotyping assay. Regulatory role of the associated variants was assessed using GTExPortal, RegulomeDB score, HaploReg and ENCODE histone ChIP-seq data. Expression of IL32 and its isoforms was evaluated by RT-PCR in PBMC from unexposed healthy controls (N = 25) with different genotype background and stimulated with TB antigens ESAT6 and CFP10. ∼ 200 bp around the associated variant was cloned into pGL3 promoter vector to assess enhancer activity by dual luciferase assay in cell lines.
RESULTS: Intronic variant rs9927163(G/T) was found associated with pulmonary TB, T being the risk allele (OR = 2.3(1.40-3.83, p = 0.03)), while G is the protective allele. This finding was validated in independent set of TB cases and household contacts (p = 0.0435). rs9927163 is an eQTL for the genes IL32 (p = 4.1e-10) and BICDL2 (p = 2.1e-7) in whole blood and interrupts an AP-1 binding site. ENCODE histone ChIP-seq data shows rs9927163 residing within T cell specific H3K4me3 peak. The G allele is associated with greater enhancer activity in a T cell line (2.12 fold, p = 0.0059). The TT genotype showed greater normalized expression of IL32δ, a less proinflammatory isoform compared to the GT and GG genotypes together following ESAT6 (p = 0.02288) and CFP10 (p = 0.04595) treatment. This indicates that greater expression of a potentially less protective IL32 isoform within individuals with the TT genotype might be a risk factor for developing TB.
1378671 Cleaners containing bleach PROCTER & GAMBLE CO 21 Feb 1972 [22 Feb 1971] 7963/72 Heading C5D [Also in Division D1] A chlorine-free, dry bleach composition which may be used for cleaning sinks, dentures and textiles comprises: (A) from 8 to 60% by weight of a bleaching agent selected from: (i) sodium monopersulphate, (ii) potassium monopersulphate, (iii) an organic peroxyacid or water-soluble salt thereof, said peroxyacid having the general formula wherein R is a substituted (e.g. by Cl), unsubstituted alkylene, or arylene group and Y is a group providing an anionic moiety in aqueous solution, e.g. -COO-, SO 3  or -CO.OO-, and (iv) mixtures thereof; (B) from 10 to 60% by weight of a quaternary ammonium compound of the general formula  wherein R 1  is an alkyl group containing from 12 to 20 carbon atoms; R 2  is selected from alkyl groups containing from 1 to 14 carbon atoms, cycloalkyl groups containing from 5 to 8 carbon atoms, carboxymethyl groups, aryl groups containing from 6 to 8 carbon atoms, alkaryl groups containing from 7 to 10 carbon atoms, pyridyl, and groups of the general formula -(C 3 H 6 O) a (C 2 H 4 O) b H, wherein a and b are 0 or integers and a+b is from 1 to 50; R 3 , R 4  and R 5  are each selected from alkyl groups containing from 1 to 3 carbon atoms, aryl groups containing from 6 to 8 carbon atoms, cycloalkyl groups containing from 5 to 8 carbon atoms, carboxymethyl groups, alkaryl groups containing from 7 to 10 carbon atoms, pyridyl, and groups of the general formula wherein a and b are 0 or integers and a+b is from 1 to 50; R 6  represents one of the groups given for R 3 , R 4  and R 5  or is H; R 7  is an alkylene group containing from 1 to 3 carbon atoms, an arylene group containing from 5 to 8 carbon atoms or a group of the formula wherein X is a non-interfering water-soluble salt forming mono- or divalent anion; and wherein n is 1 when X is a monovalent anion and n is 2 when X is a divalent anion; and (C) from 10 to 75% by weight of a buffering agent effective to maintain a solution pH of from 7 to 10 when said composition is dissolved in water for bleaching, e.g. phosphates, hydrogen phosphates, carbonates or bicarbonates. An aqueous bleaching solution may be formed by dissolving components (A) and (B) in water whilst maintaining the pH between 7 and 10. The aqueous solutions can be used for bleaching and softening cotton fabrics.
This is a multicenter, prospective, observational, registration study. There are nine centers involved in the study. The investigators set up a more detailed classification system for spinal vascular malformations. In accordance with inclusion criteria and exclusion criteria, this cohort study will include 380 samples in the study period of three years. According to the spinal angiography, the correct diagnosis and treatment strategy will be made. The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc. All the enrolled patients will be visited a total of four times, postoperative day 1 and postoperative day 7, followed up postoperative 3 months and 12 months. The anatomical cure rate and spinal cord function will be assessed objectively. All data will be recorded in the network database platform.
The invention discloses a homatropine hydrobromide in situ gel preparation for eye dripping and the preparation method thereof, which relates to an ion sensitive eye in situ gel preparation and the preparation method thereof. The eye in situ gel takes homatropine hydrobromide as the active ingredient, gellan gum as the gel matrix and preservative, isotonic regulator, pH regulator and ultra-pure water as the assistants for the preparation. The in situ gel preparation of the invention makes use of complex of gel matrix, gellan gum and Ca<2+>, Na<+>, K<+> and other metal ions in tear to form stable hydrogen bonds, so as to be in the gel state. The in situ gel preparation is in liquid state in vitro and is in gel state when the invention is dripped in eye. The preparation combines the advantages of eye drops and eye ointments or gels and at the same time avoids the shortcomings of the two. Furthermore, the usage is convenient, the drug loss is reduced and the local bioavailability is improved.
The present disclosure is directed to an in-liquid laser-based method for fabricating a solution of fine particles of amorphous solid medicinal compounds, a solution of fine particles of amorphous medicinal agents made with the method, and fine particles made with the method. By using a target solidified via a phase transition process to covert an initial crystalline structure into an amorphous solid, technical difficulties with handling a hydraulically-pressed target are overcome. The laser-based ablation process produces amorphous solid medicinal compound fine particles, which improves the bioavailability and solubility of the medicinal compound. The improvement results from a combination of: disordered crystalline structure and enlarged relative surface area by particle size reduction. The laser based method may be carried out with ultrashort pulsed laser systems, or with UV nanosecond lasers. Results obtained with an ultrashort near IR laser and a UV nanosecond laser show formation of amorphous solid curcumin fine particles.
Objectives: Primary cardiac involvement (SSc-PHI) in systemic sclerosis is an important prognostic factor. We aimed to characterize and identify subclinical SSc-PHI using cardiovascular MRI to determine whether disease severity and serum biomarkers are associated with subclinical SSc-PHI. Methods: A total of 26 patients with SSc who had no history of cardiovascular disease or pulmonary hypertension underwent 3 T-enhanced cardiovascular MRI. Measurements included native T1, extracellular volume, advanced gadolinium enhancement, T2 mapping, and left ventricular volume function. Troponin T and N telencephalic natriuretic peptide precursors were also determined. Results: LGE was observed in 13 of 26 patients (50.0%), suggesting focal fibrosis, and T2 mapping was significantly higher in the dcSSc group than in the lcSSc group (P=0.009). Left ventricular volume and function were within the normal range in all patients, but final systolic left ventricular volume was significantly higher in dcSSc than in lcSSc (P=0.021). The modified Rodnan skin score (mRSS) was significantly higher in patients with LGE focal fibrosis (P=0.019). Logistic regression analysis confirmed the association between mRSS and LGE (OR=1.224, P=0.037). In multivariate analysis, T2 mapping was negatively correlated with disease course, and was correlated with dcSSc and fingertip ulcer (R2=0.711, P=0.018, P=0.013, P=0.030). Troponin T was correlated with T2 mapping (r=0.555, P=0.049). Conclusions: Subclinical SSc-PHI is characterized by diffuse and focal myocardial fibrosis, but preserves myocardial systolic function. Subclinical SSC-Phi is associated with TNT, SSc disease severity, and complex peripheral vascular disease. These data provide information for identifying individuals at risk of SSc-PHI.
Multiple pathophysiologic and biomolecular processes lead to bullae, including disruption of adhesion molecules, accumulation of cell injury, and traumatic injury. Blistering disorders of the foot can cause symptoms such as pruritus, pain, and drainage and significantly impact quality of life. Microbiologic and histopathologic examination of tissue specimens should be considered for concerns regarding atypical etiology.This retrospective case series describes patients seen in a community hospital outpatient wound center in southeastern Wisconsin between January 2021 and June 2023 for atypical blistering disorders of the foot. The cases herein describe the history, clinical presentation, and treatment of three atypical blistering disorders of the foot. An 86-year-old man presented complaining of intensely pruritic blistering lesions to both feet. Histopathologic findings indicated eosinophilic infiltrate, and the patient was treated for an eosinophilic drug reaction. A 65-year-old man presented complaining of multiple painful blisters to the plantar aspect of both feet. Histopathologic examination of unroofed blister indicated bullous tinea. Finally, a 44-year-old man with long-standing type 1 diabetes presented complaining of a several-week history of a single blister to his anterior right foot of unknown etiology. The patient was diagnosed with bullosis diabeticorum.Blistering disorders of the foot are diagnostic challenges; diagnostic clarity is assisted by thorough history, clinical presentation, treatment response, microbial analysis, and histopathologic findings.
Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
FIELD: medicine. SUBSTANCE: composition has at least two drugs selected from a group containing renin inhibitor, inhibitor of enzyme transforming angiotensin I and angiotensin II antagonist, both inhibitor and antagonist being present in the amount enough for achieving synergistic therapeutic result like reducing arterial blood pressure and treating congestive heart failure in mammals. The method involves administering (in turn or simultaneously) at least two of the therapeutic means to mammals. The drugs are selected from the mentioned group at a dose enough for achieving synergistic therapeutic result. EFFECT: enhanced effectiveness of treatment. 8 cl, 3 tbl
The invention discloses a preparation method of a calcium phosphate and vitamin D composite microcapsule, wherein a hydrogen phosphate aqueous solution is used as an internal water phase, vitamin D is dissolved in an organic solvent, and an emulsifier is added to emulsify to form W/O type colostrum. The calcium salt water solution is used as an external water phase, and an emulsifier is added to emulsify to form W/O/W multiple emulsion. The hydrogen phosphate and calcium salt in the inner and outer water phases react to generate calcium phosphate in different forms, and vitamin D is absorbed in the calcium phosphate to form a core material. Adding the capsule core material into sodium alginate solution, reacting with calcium salt to generate calcium alginate, coating calcium phosphate and vitamin D, solidifying to obtain capsule, settling, washing, and drying. The microcapsule prepared by the invention is obtained by a double emulsification method and calcium alginate sedimentation, and the vitamin D and the calcium phosphate are uniformly mixed, so that the microcapsule has high encapsulation efficiency and good stability. The invention is a microcapsule preparation, which is beneficial to the absorption of a calcium supplement preparation in the gastrointestinal tract.
A polycarbonate dimethacrylate which is the condensation product of 2 parts of hydroxyalkylmethacrylate of the formula.    <IMAGE>   in which A is C1-C6 alkylene, and 1 part of a bis(chloroformate) of the formula    <IMAGE>   in which R is C2-C5 alkylene having at least two carbon atoms in its principal chain and n is an integer from 1 to 4, is usable, admixed with a secondary monomer suitable for dental applications, such as BIS-GMA; UDMA or the like, as an adhesive system for dental restorative materials. Particularly useful is the novel condensation product of 2-hydroxyethylmethacrylate and triethylene glycol bis(chloroformate). Dental adhesives containing these components are suitable for application to enamel, pretreated dentin, porcelain and metallic surfaces. The dentin surfaces are pretreated by application of an alcoholic solution of an alkali metal salt of benzene sulfinic acid. The resinous adhesives of the invention can be used in dental compositions which are visible lighting curing, self-curing, dual curing, heat and pressuring curing, or any combination thereof. Where the resinous adhesive is a self-curing adhesive, the polymerization accelerator, which is a tertiary amine such as dihydroxyethyl-p-toluidine, can optionally be incorporated into the alcoholic pretreatment solution. The condensation product is also suitable for use in filled compositions in which the filler material comprises inorganic silicates.
The usual adult dosage of nicotinic acid is 1 to 2 grams two or three times a day. Doses should be individualized according to the patient's response. Start with one-half tablet (250 mg) as a single daily dose following the evening meal. The frequency of dosing and total daily dose can be increased every four to seven days until the desired LDL cholesterol and/or triglyceride level is achieved or the first-level therapeutic dose of 1.5 to 2 grams/day is reached. If the patient's hyperlipidemia is not adequately controlled after 2 months at this level, the dosage can then be increased at two to four week intervals to 3 grams/day (1 gram three times per day). In patients with marked lipid abnormalities, a higher dose is occasionally required, but generally should not exceed 6 grams/day.

Flushing of the skin appears frequently and can be minimized by pretreatment with aspirin or non-steroidal anti-inflammatory drugs. Tolerance to this flushing develops rapidly over the course of several weeks. Flushing, pruritus, and gastrointestinal distress are also greatly reduced by slowly increasing the dose of nicotinic acid and avoiding administration on an empty stomach.

Sustained-release (modified-release, timed-release) nicotinic acid preparations should not be substituted for equivalent doses of immediate-release (crystalline) nicotinic acid.